Structural and functional correlates of enhanced antiviral immunity generated by heteroclitic CD8 T cell epitopes

Journal of Immunology

Volumn 192, Issue 11, 2014, Pages 5245-5256

  Trujillo, Jonathan A ^a   Gras, Stephanie ^b   Twist, Kelly Anne ^b   Croft, Nathan P ^b   Channappanavar, Rudragouda ^c   Rossjohn, Jamie ^b,d   Purcell, Anthony W ^b   Perlman, Stanley ^a,c  

^a UNIVERSITY OF IOWA   (United States)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF IOWA   (United States)

^d CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MEMBRANE PROTEIN; PEPTIDE S510; PEPTIDE S598; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN FUNCTION; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPLEX FORMATION; CONTROLLED STUDY; CORONAVIRUS INFECTION; CROSS REACTION; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN EXPRESSION;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CORONAVIRUS; CORONAVIRUS INFECTIONS; EPITOPES, T-LYMPHOCYTE; HELA CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MICE; MUTATION, MISSENSE; PEPTIDES; VIRAL PROTEINS;

EID: 84901268342     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400111     Document Type: Article

References (57)

1. Croft, N. P., and A. W. Purcell. 2011. Peptidomimetics: modifying peptides in the pursuit of better vaccines. Expert Rev. Vaccines 10: 211-226.
2. Purcell, A. W., J. McCluskey, and J. Rossjohn. 2007. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov. 6: 404-414.
3. Alexander-Miller, M. A., G. R. Leggatt, and J. A. Berzofsky. 1996. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA 93: 4102-4107.
4. Zeh, H. J., III, D. Perry-Lalley, M. E. Dudley, S. A. Rosenberg, and J. C. Yang. 1999. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162: 989-994.
5. Gallimore, A., T. Dumrese, H. Hengartner, R. M. Zinkernagel, and H. G. Rammensee. 1998. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J. Exp. Med. 187: 1647-1657.
6. Sedlik, C., G. Dadaglio, M. F. Saron, E. Deriaud, M. Rojas, S. I. Casal, and C. Leclerc. 2000. In vivo induction of a high-avidity, high-frequency cytotoxic Tlymphocyte response is associated with antiviral protective immunity. J. Virol. 74: 5769-5775.
7. Neveu, B., E. Debeaupuis, K. Echasserieau, B. le Moullac-Vaidye, M. Gassin, L. Jegou, J. Decalf, M. Albert, N. Ferry, J. Gournay, et al. 2008. Selection of high-avidity CD8 T cells correlates with control of hepatitis C virus infection. Hepatology 48: 713-722.
8. Almeida, J. R., D. A. Price, L. Papagno, Z. A. Arkoub, D. Sauce, E. Bornstein, T. E. Asher, A. Samri, A. Schnuriger, I. Theodorou, et al. 2007. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 204: 2473-2485.
9. Bullock, T. N., D. W. Mullins, T. A. Colella, and V. H. Engelhard. 2001. Manipulation of avidity to improve effectiveness of adoptively transferred CD8+ T cells for melanoma immunotherapy in human MHC class I-transgenic mice. J. Immunol. 167: 5824-5831.
10. Speiser, D. E., P. Baumgaertner, V. Voelter, E. Devevre, C. Barbey, N. Rufer, and P. Romero. 2008. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc. Natl. Acad. Sci. USA 105: 3849-3854.
11. Zhang, Y., Y. Liu, K. M. Moxley, L. Golden-Mason, M. G. Hughes, T. Liu, M. H. Heemskerk, H. R. Rosen, and M. I. Nishimura. 2010. Transduction of human T cells with a novel T-cell receptor confers anti-HCV reactivity. PLoS Pathog. 6: e1001018.
12. Kessels, H. W., M. C. Wolkers, M. D. van den Boom, M. A. van der Valk, and T. N. Schumacher. 2001. Immunotherapy through TCR gene transfer. Nat. Immunol. 2: 957-961.
13. Dyall, R., W. B. Bowne, L. W. Weber, J. LeMaoult, P. Szabo, Y. Moroi, G. Piskun, J. J. Lewis, A. N. Houghton, and J. Nikolić-Zugić. 1998. Heteroclitic immunization induces tumor immunity. J. Exp. Med. 188: 1553-1561.
14. Butler, N. S., A. Theodossis, A. I. Webb, R. Nastovska, S. H. Ramarathinam, M. A. Dunstone, J. Rossjohn, A. W. Purcell, and S. Perlman. 2008. Prevention of cytotoxic T cell escape using a heteroclitic subdominant viral T cell determinant. PLoS Pathog. 4: e1000186.
15. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4: 321-327.
16. Borbulevych, O. Y., T. K. Baxter, Z. Yu, N. P. Restifo, and B. M. Baker. 2005. Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design. J. Immunol. 174: 4812-4820.
17. Chen, J. L., G. Stewart-Jones, G. Bossi, N. M. Lissin, L. Wooldridge, E. M. Choi, G. Held, P. R. Dunbar, R. M. Esnouf, M. Sami, et al. 2005. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J. Exp. Med. 201: 1243-1255.
18. Bullock, T. N., D. W. Mullins, and V. H. Engelhard. 2003. Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells. J. Immunol. 170: 1822-1829.
19. Dzutsev, A. H., I. M. Belyakov, D. V. Isakov, D. H. Margulies, and J. A. Berzofsky. 2007. Avidity of CD8 T cells sharpens immunodominance. Int. Immunol. 19: 497-507.
20. Wherry, E. J., K. A. Puorro, A. Porgador, and L. C. Eisenlohr. 1999. The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. J. Immunol. 163: 3735-3745.
21. Rubio, V., T. B. Stuge, N. Singh, M. R. Betts, J. S. Weber, M. Roederer, and P. P. Lee. 2003. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat. Med. 9: 1377-1382.
22. Bergmann, C. C., T. E. Lane, and S. A. Stohlman. 2006. Coronavirus infection of the central nervous system: host-virus stand-off. Nat. Rev. Microbiol. 4: 121-132.
23. van Boheemen, S., M. de Graaf, C. Lauber, T. M. Bestebroer, V. S. Raj, A. M. Zaki, A. D. Osterhaus, B. L. Haagmans, A. E. Gorbalenya, E. J. Snijder, and R. A. Fouchier. 2012. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio 3: e00473-12.
24. Castro, R. F., and S. Perlman. 1995. CD8+ T-cell epitopes within the surface glycoprotein of a neurotropic coronavirus and correlation with pathogenicity. J. Virol. 69: 8127-8131.
25. Pewe, L., S. B. Heard, C. Bergmann, M. O. Dailey, and S. Perlman. 1999. Selection of CTL escape mutants in mice infected with a neurotropic coronavirus: quantitative estimate of TCR diversity in the infected central nervous system. J. Immunol. 163: 6106-6113.
26. Pewe, L., S. Xue, and S. Perlman. 1998. Infection with cytotoxic T-lymphocyte escape mutants results in increased mortality and growth retardation in mice infected with a neurotropic coronavirus. J. Virol. 72: 5912-5918.
27. Williams, R. K., G. S. Jiang, and K. V. Holmes. 1991. Receptor for mouse hepatitis virus is a member of the carcinoembryonic antigen family of glycoproteins. Proc. Natl. Acad. Sci. USA 88: 5533-5536.
28. Anghelina, D., L. Pewe, and S. Perlman. 2006. Pathogenic role for virus-specific CD4 T cells in mice with coronavirus-induced acute encephalitis. Am. J. Pathol. 169: 209-222.
29. Croft, N. P., S. A. Smith, Y. C. Wong, C. T. Tan, N. L. Dudek, I. E. Flesch, L. C. Lin, D. C. Tscharke, and A. W. Purcell. 2013. Kinetics of antigen expression and epitope presentation during virus infection. PLoS Pathog. 9: e1003129.
30. Tan, C. T., N. P. Croft, N. L. Dudek, N. A. Williamson, and A. W. Purcell. 2011. Direct quantitation of MHC-bound peptide epitopes by selected reaction monitoring. Proteomics 11: 2336-2340.
31. Zhao, J., J. Zhao, and S. Perlman. 2009. De novo recruitment of antigenexperienced and naive T cells contributes to the long-term maintenance of antiviral T cell populations in the persistently infected central nervous system. J. Immunol. 183: 5163-5170.
32. Wu, G. F., A. A. Dandekar, L. Pewe, and S. Perlman. 2000. CD4 and CD8 T cells have redundant but not identical roles in virus-induced demyelination. J. Immunol. 165: 2278-2286.
33. Pham, N. L., V. P. Badovinac, and J. T. Harty. 2009. A default pathway of memory CD8 T cell differentiation after dendritic cell immunization is deflected by encounter with inflammatory cytokines during antigen-driven proliferation. J. Immunol. 183: 2337-2348.
34. Chen, A. T., M. Cornberg, S. Gras, C. Guillonneau, J. Rossjohn, A. Trees, S. Emonet, J. C. de la Torre, R. M. Welsh, and L. K. Selin. 2012. Loss of antiviral immunity by infection with a virus encoding a cross-reactive pathogenic epitope. PLoS Pathog. 8: e1002633.
35. Kabsch, W. 2010. Integration, scaling, space-group assignment and post-refinement. Acta Crystallogr. D Biol. Crystallogr. 66: 133-144.
36. Read, R. J. 2001. Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr. D Biol. Crystallogr. 57: 1373-1382.
37. Collaborative Computational Project, Number 4. 1994. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50: 760-763.
38. Adams, P. D., P. V. Afonine, G. Bunkóczi, V. B. Chen, I. W. Davis, N. Echols, J. J. Headd, L. W. Hung, G. J. Kapral, R. W. Grosse-Kunstleve, et al. 2010. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66: 213-221.
39. Bricogne, G., E. Blanc, M. Brandl, C. Flensburg, P. Keller, W. Paciorek, P. Roversi, A. Sharff, O. S. Smart, C. Vonrhein, and T. O. Womack. 2011. Buster Version 2.10. Global Phasing, Cambridge, U.K.
40. Emsley, P., B. Lohkamp, W. G. Scott, and K. Cowtan. 2010. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66: 486-501.
41. Anton, L. C., J. W. Yewdell, and J. R. Bennink. 1997. MHC class I-associated peptides produced from endogenous gene products with vastly different efficiencies. J. Immunol. 158: 2535-2542.
42. Porgador, A., J. W. Yewdell, Y. Deng, J. R. Bennink, and R. N. Germain. 1997. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6: 715-726.
43. Butler, N. S., A. Theodossis, A. I. Webb, M. A. Dunstone, R. Nastovska, S. H. Ramarathinam, J. Rossjohn, A. W. Purcell, and S. Perlman. 2008. Structural and biological basis of CTL escape in coronavirus-infected mice. J. Immunol. 180: 3926-3937.
44. Burrows, S. R., Z. Chen, J. K. Archbold, F. E. Tynan, T. Beddoe, L. Kjer-Nielsen, J. J. Miles, R. Khanna, D. J. Moss, Y. C. Liu, et al. 2010. Hard wiring of T cell receptor specificity for the major histocompatibility complex is underpinned by TCR adaptability. Proc. Natl. Acad. Sci. USA 107: 10608-10613.
45. Gras, S., S. R. Burrows, S. J. Turner, A. K. Sewell, J. McCluskey, and J. Rossjohn. 2012. A structural voyage toward an understanding of the MHC-Irestricted immune response: lessons learned and much to be learned. Immunol. Rev. 250: 61-81.
46. Valkenburg, S. A., S. Gras, C. Guillonneau, L. A. Hatton, N. A. Bird, K. A. Twist, H. Halim, D. C. Jackson, A. W. Purcell, S. J. Turner, et al. 2013. Preemptive priming readily overcomes structure-based mechanisms of virus escape. Proc. Natl. Acad. Sci. USA 110: 5570-5575.
47. Fikes, J. D., and A. Sette. 2003. Design of multi-epitope, analogue-based cancer vaccines. Expert Opin. Biol. Ther. 3: 985-993.
48. Speiser, D. E., D. Kyburz, U. Stubi, H. Hengartner, and R. M. Zinkernagel. 1992. Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities. Low T cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide-coated target cells but not for in vivo protection. J. Immunol. 149: 972-980.
49. Dijkman, R., M. F. Jebbink, S. M. Koekkoek, M. Deijs, H. R. Jónsdóttir, R.Molenkamp,M. Ieven, H. Goossens, V. Thiel, and L. van der Hoek. 2013. Isolation and characterization of current human coronavirus strains in primary human epithelial cell cultures reveal differences in target cell tropism. J. Virol. 87: 6081-6090.
50. Wherry, E. J., M. J. McElhaugh, and L. C. Eisenlohr. 2002. Generation of CD8+ T cell memory in response to low, high, and excessive levels of epitope. J. Immunol. 168: 4455-4461.
51. Bullock, T. N., T. A. Colella, and V. H. Engelhard. 2000. The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice. J. Immunol. 164: 2354-2361.
52. Theodossis, A., C. Guillonneau, A. Welland, L. K. Ely, C. S. Clements, N. A. Williamson, A. I. Webb, J. A. Wilce, R. J. Mulder, M. A. Dunstone, et al. 2010. Constraints within major histocompatibility complex class I restricted peptides: presentation and consequences for T-cell recognition. Proc. Natl. Acad. Sci. USA 107: 5534-5539.
53. Archbold, J. K., W. A. Macdonald, S. Gras, L. K. Ely, J. J. Miles, M. J. Bell, R. M. Brennan, T. Beddoe, M. C. Wilce, C. S. Clements, et al. 2009. Natural micropolymorphism in human leukocyte antigens provides a basis for genetic control of antigen recognition. J. Exp. Med. 206: 209-219.
54. Macdonald, W. A., Z. Chen, S. Gras, J. K. Archbold, F. E. Tynan, C. S. Clements, M. Bharadwaj, L. Kjer-Nielsen, P. M. Saunders, M. C. Wilce, et al. 2009. T cell allorecognition via molecular mimicry. Immunity 31: 897-908.
55. Rammensee, H. G., K. Falk, and O. Rötzschke. 1993. Peptides naturally presented by MHC class I molecules. Annu. Rev. Immunol. 11: 213-244.
56. Zhao, J., J. Zhao, and S. Perlman. 2010. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J. Virol. 84: 9318-9325.
57. Zhao, J., J. Zhao, N. Van Rooijen, and S. Perlman. 2009. Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice. PLoS Pathog. 5: e1000636.